🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,180 results for “Takeda Pharmaceuticals International AG” Clear

  1. Immune Globulin Intravenous (IGIV)

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  2. Immune Globulin Intravenous (human), 10%

    Takeda Pharmaceuticals International AG

    Multifocal Motor Neuropathy

    phase 3 mab completed

    1 trial

  3. Immune Globulin Subcutaneous (Human), 20%

    Takeda Pharmaceuticals International AG

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  4. Intranasal Fentanyl Spray (INFS)

    Takeda Pharmaceuticals International AG

    Break Through Pain

    phase 3 small molecule completed

    1 trial

  5. Ixazomib

    Takeda Pharmaceuticals International AG

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  6. Ixazomib Citrate

    Takeda Pharmaceuticals International AG

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials

  7. Ixazomib, thalidomide, & dexamethasone (ITD) re-induction

    Takeda Pharmaceuticals International AG

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  8. KIOVIG 100 mg/ml solution for infusion, TECVAYLI 90 mg/mL solution for injection, TECVAYLI 10 mg/mL solution for injection, KIOVIG 100 mg/ml solution for infusion

    Takeda Pharmaceuticals International AG

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  9. LDX

    Takeda Pharmaceuticals International AG

    ADHD

    phase 3 small molecule completed

    1 trial

  10. LDX 30 mg

    Takeda Pharmaceuticals International AG

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  11. Lanadelumab

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  12. Lanadelumab

    Takeda Pharmaceuticals International AG

    Angioedema

    phase 3 small molecule completed

    2 trials

  13. Lanadelumab

    Takeda Pharmaceuticals International AG

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    2 trials

  14. Lansoprazole

    Takeda Pharmaceuticals International AG

    Stomach Ulcer

    phase 3 small molecule completed

    2 trials

  15. Lansoprazole and naproxen and aspirin

    Takeda Pharmaceuticals International AG

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  16. Lansoprazole microgranules suspension

    Takeda Pharmaceuticals International AG

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  17. Lapaquistat Acetate

    Takeda Pharmaceuticals International AG

    Dyslipidemia

    phase 3 small molecule completed

    2 trials

  18. Lapaquistat acetate

    Takeda Pharmaceuticals International AG

    Hypercholesterolemia

    phase 3 small molecule completed

    4 trials

  19. Lapaquistat acetate and atorvastatin

    Takeda Pharmaceuticals International AG

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  20. Lapaquistat acetate and current lipid-lowering treatment

    Takeda Pharmaceuticals International AG

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  21. Lapaquistat acetate and lipid-lowering therapy

    Takeda Pharmaceuticals International AG

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  22. Lapaquistat acetate and rosuvastatin

    Takeda Pharmaceuticals International AG

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  23. Lapaquistat acetate and simvastatin

    Takeda Pharmaceuticals International AG

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  24. Lapaquistat acetate and stable statin therapy

    Takeda Pharmaceuticals International AG

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources